TAG and TB CAB Issue Open Letter to Janssen
TAG and TB CAB issue an open letter to Janssen, bedaquiline’s sponsor, about the need to accelerate pediatric research, to determine the safety of using bedaquiline and delamanid together, and to support Janssen’s compassionate use program to provide access to bedaquiline for people in urgent need in places where the drug has not yet been approved.